Mylan, IRS Ink Deal To Avoid Trial On Nebivolol Transaction
Mylan Inc. and the IRS have struck a last-minute deal to avert a $100 million tax trial relating to the drugmaker's transaction with Forest Laboratories Holdings Ltd. over the antihypertensive compound...To view the full article, register now.
Already a subscriber? Click here to view full article